Ginkgo Bioworks Holdings (DNA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Ginkgo Bioworks Holdings

NYSE•Healthcare•Biotechnology

$6.950.00(0.00%)Market closed

Market Cap

$438.39M

P/S

3.9x

P/B

1.0x

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

How this company scores

WeakMetricSide Score: 38/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (6/25).

Profitability11/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredProfit converts from growthNet cash positionImproving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 3.9x5y range 0.0x – 38.9x

Currently near its 19-quarter median.

P/B · 1.0x5y range 0.0x – 10.4x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $438.39M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $111.86M
Q. Revenue: $20.16M
TTM EBITDA: $-237.75M
TTM Op. Income: $-290.69M
Q. Op. Income: $-58.55M
TTM Net Income: $-290.80M
Q. Net Income: $-46.71M
EPS: $-0.75
Shares Out.: $62.09M

$111.86M in TTM revenue declined 51.5% YoY, reaching $20.16M last quarter. TTM EBITDA of $-237.75M and TTM operating income of $-290.69M show growth is flowing through to the bottom line. However, net income is negative at $290.80M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 5 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 91.5%
EBITDA Margin: -229.4%
Op. Margin: -290.5%
Net Margin: -231.7%

Op. margin of -290.5% is down 158.3% YoY — costs are rising relative to revenue. Net margin at -231.7% and gross margin of 91.5% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 120% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 3.9x
P/B Ratio: 1.0x

P/S of 3.9x and P/B of 1.0x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $990.05M
Cash: $84.53M
Long-Term Debt: N/A
Book Value: $420.28M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-42.17M
TTM Free Cash Flow: $-172.45M
FCF Margin: -154.2%
FCF / Net Income: 0.6

TTM FCF of $-172.45M on $-42.17M in operating cash flow. The FCF / Net Income ratio of 0.6x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is up 37% — a weakening trend.